4D Molecular Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

4D Molecular Therapeutics

08/11/2022 23:11

* 4D Molecular Therapeutics Inc  FDMT.OQ  reported a
quarterly
adjusted loss of 79 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 91 cents per share.
    * Revenue fell 63.4% to $500.00 thousand from a year ago;
analysts
expected $876.25 thousand. 
    * 4D Molecular Therapeutics Inc's reported EPS for the
quarter was
a loss of 79 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * 4D Molecular Therapeutics Inc shares had risen by 3.5%
this
quarter and lost 62.1% so far this year.
    * The company reported a quarterly loss of $25.69 million.
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 11:10 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.91          -0.79          Beat
 Jun. 30 2022      -0.85          -0.87          Missed
 Mar. 31 2022      -0.81          -0.82          Missed
 Dec. 31 2021      -0.86          -0.85          Beat